1. Home
  2. KWR vs LSBPW Comparison

KWR vs LSBPW Comparison

Compare KWR & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KWR
  • LSBPW
  • Stock Information
  • Founded
  • KWR 1918
  • LSBPW N/A
  • Country
  • KWR United States
  • LSBPW China
  • Employees
  • KWR N/A
  • LSBPW 758
  • Industry
  • KWR Major Chemicals
  • LSBPW Biotechnology: Pharmaceutical Preparations
  • Sector
  • KWR Industrials
  • LSBPW Health Care
  • Exchange
  • KWR Nasdaq
  • LSBPW Nasdaq
  • Market Cap
  • KWR N/A
  • LSBPW N/A
  • IPO Year
  • KWR 1985
  • LSBPW N/A
  • Fundamental
  • Price
  • KWR $141.68
  • LSBPW $0.06
  • Analyst Decision
  • KWR Buy
  • LSBPW
  • Analyst Count
  • KWR 3
  • LSBPW 0
  • Target Price
  • KWR $177.33
  • LSBPW N/A
  • AVG Volume (30 Days)
  • KWR 129.2K
  • LSBPW N/A
  • Earning Date
  • KWR 02-24-2025
  • LSBPW N/A
  • Dividend Yield
  • KWR 1.37%
  • LSBPW N/A
  • EPS Growth
  • KWR 647.22
  • LSBPW N/A
  • EPS
  • KWR 6.82
  • LSBPW N/A
  • Revenue
  • KWR $1,862,709,000.00
  • LSBPW N/A
  • Revenue This Year
  • KWR N/A
  • LSBPW N/A
  • Revenue Next Year
  • KWR $1.95
  • LSBPW N/A
  • P/E Ratio
  • KWR $20.76
  • LSBPW N/A
  • Revenue Growth
  • KWR N/A
  • LSBPW N/A
  • 52 Week Low
  • KWR $124.66
  • LSBPW N/A
  • 52 Week High
  • KWR $207.83
  • LSBPW N/A
  • Technical
  • Relative Strength Index (RSI)
  • KWR 52.38
  • LSBPW N/A
  • Support Level
  • KWR $139.44
  • LSBPW N/A
  • Resistance Level
  • KWR $139.46
  • LSBPW N/A
  • Average True Range (ATR)
  • KWR 3.85
  • LSBPW 0.00
  • MACD
  • KWR 0.81
  • LSBPW 0.00
  • Stochastic Oscillator
  • KWR 63.43
  • LSBPW 0.00

About LSBPW LakeShore Biopharma Co. Ltd

LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.

Share on Social Networks: